Drone strike shatters Indian‑linked pharmaceutical factory
New Delhi. A Russian drone assault on a Kusum Group manufacturing unit in Sumy, Ukraine, left the main building in ruins, killed an engineer and wounded several workers. The plant, which had been operating throughout the conflict, suffered multiple hits that devastated its engineering wing and forced an emergency evacuation.
Preliminary assessments peg the losses at roughly Rs 400 crore, though the company says a full audit is still underway. With such extensive damage, the facility is expected to remain offline for an indeterminate period.
Indian roots, Ukrainian footprint
The Kusum Group entered the Ukrainian market in 1994, initially distributing Indian‑sourced medicines. By 2009 it had built a full‑scale production complex in Sumy, complementing its 2007 manufacturing hub in India. Today the conglomerate offers over 50 generic drugs and serves markets across Ukraine, Uzbekistan, Kazakhstan and the Philippines, branding itself as a Ukrainian pharma firm with Indian heritage.
Operations continued despite war – until now
Even as hostilities raged, the Sumy plant kept churning out medicines for local and regional patients. The latest strike, however, has halted production and prompted the group to weigh shifting vulnerable output to its Indian sites.
Ukrainian President Volodymyr Zelenskyy condemned the attack, confirming that a drone barrage targeted the pharmaceutical complex and resulted in a fatality. The incident underscores the mounting danger faced by civilian and commercial installations in conflict zones.
Wider ramifications
The destruction of the Sumy plant not only threatens the supply of essential generics in the region but also raises questions about the resilience of cross‑border supply chains during armed conflict. A detailed evaluation will determine the true financial and operational fallout for the Indian‑linked group.



